Bayer, J&J’s Xarelto Matches Warfarin in Rocket Trial
This article is for subscribers only.
Bayer AG’s blood thinner Xarelto matched the standard therapy at preventing blood clots in patients with an irregular heartbeat, results that may determine its success in a market worth as much as $14 billion a year.
Xarelto was as effective as warfarin, the standard treatment over the past half century, Leverkusen, Germany-based Bayer said yesterday in the first comparison between the two drugs. Xarelto had “comparable” safety and rates of bleeding versus the standard, Bayer said.